Check-Cap

48 articles with Check-Cap

• Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights

  11/18/2020

  Submitted Investigational Device Exemption (IDE) application to the FDA for Pivotal Study of C-Scan®

• Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights

  8/6/2020

  IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021.

• Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds

  7/23/2020

  Check-Cap Ltd. announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share.

• Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification

  6/5/2020

  Check-Cap Ltd . (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan ® , the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company received a let

• Check-Cap Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/27/2020

  Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020

• Check-Cap Ltd. Announces $3.0 Million Registered Direct Offering

  5/9/2020

  Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.

• Check-Cap Ltd. Announces $4.5 Million Registered Direct Offering

  4/30/2020

  Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.

• Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering

  4/20/2020

  Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.

• Check-Cap Provides Update on COVID-19 Pandemic Impact on Operational and Clinical Activities

  4/6/2020

  Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company's operational and clinical activities.

• 

  BioSpace Global Roundup, Jan. 2

  1/2/2020

  Companies from across the globe announce updates to their business and pipeline.

• Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System

  12/30/2019

  Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020

• Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights

  11/6/2019

  Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System

• Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference

  10/24/2019

  Check-Cap Ltd. announced that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the Dawson James 5th Annual Small Cap Growth Conference, being held October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.

• 

  BioSpace Movers & Shakers, Sept. 27

  9/27/2019

  Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.

• Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  9/3/2019

  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), announced today that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference, being held September 8-10, 2019 in New York.

• 

  BioSpace Global Roundup, Aug. 22

  8/22/2019

  Companies from across the globe provide updates on their business and pipelines.

• Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare

  8/19/2019

  GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S.

• 

  BioSpace Global Roundup, July 11

  7/11/2019

  Companies from across Europe, Asia and around the globe share pipeline and business updates.

• Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System

  7/9/2019

  Check-Cap Ltd., announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.

• 

  BioSpace Movers and Shakers, June 7

  6/7/2019

  Pharma and biotech companies strengthen their executive and leadership teams with new appointments.